Company Announcements

Publication of Suppl.Prospcts

Source: RNS
RNS Number : 5035A
Bank of Nova Scotia
29 May 2019
 

The Bank of Nova Scotia and Scotiabank Europe plc

May 29, 2019

 

Publication of Prospectus Supplement

 

The Fifth Supplement (as defined below) to the Prospectus dated July 6, 2018 (as supplemented by the first supplement to the Prospectus dated July 20, 2018 (the "First Supplement"), the second supplement to the Prospectus dated August 29, 2018 (the "Second Supplement"), the third supplement to the Prospectus dated November 28, 2018 (the "Third Supplement") and the fourth supplement to the Prospectus dated February 28, 2019 (the "Fourth Supplement")) (such Prospectus as supplemented, the "Prospectus") has been approved by the UK Listing Authority and is available for viewing:

 

Fifth Supplement dated May 29, 2019 (as supplemented by the First Supplement dated July 20, 2018, the Second Supplement dated August 29, 2018, the Third Supplement dated November 28, 2018 and the Fourth Supplement dated February 28, 2019) to the Prospectus dated July 6, 2018 relating to the U.S.$20,000,000,000 Euro Medium Term Note Programme of The Bank of Nova Scotia and Scotiabank Europe plc.

 

The Fifth Supplement (the "Fifth Supplement") has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

 

To view the Fifth Supplement, including the document incorporated by reference therein, please click on the links below or, alternatively, paste the following URL into the address bar of your Internet browser:

 

Fifth Supplement dated May 29, 2019 relating to the U.S.$20,000,000,000 Euro Medium Term Note Programme of The Bank of Nova Scotia and Scotiabank Europe plc.

 

http://www.rns-pdf.londonstockexchange.com/rns/5035A_1-2019-5-29.pdf

 


Document incorporated by reference in the Prospectus:

 

              The Bank of Nova Scotia's comparative unaudited interim consolidated financial statements for the three and six month periods ended April 30, 2019 prepared in accordance with IFRS, together with the auditors' report thereon and management's discussion and analysis for the three and six month periods ended April 30, 2019, set out on pages 3 through 71 of the Bank's 2019 Second Quarter Report to Shareholders. The remainder of the Bank's 2019 Second Quarter Report to Shareholders is not incorporated and is either covered elsewhere in the Prospectus or deemed not relevant to investors.

 

http://www.rns-pdf.londonstockexchange.com/rns/5035A_2-2019-5-29.pdf

 

               

 

For further information, please contact:

 

The Bank of Nova Scotia

Scotia Plaza

40 King Street West

Toronto, Ontario

Canada M5H 1H1

 

Attn: Managing Director, Alternate Funding

Tel.: 001 416 933 7974

Fax: 001 416 945 4001

 

DISCLAIMER - INTENDED ADDRESSEES

 

Please note that the information contained in the Prospectus as supplemented by the First Supplement, the Second Supplement, the Third Supplement, the Fourth Supplement and the Fifth Supplement (the "Supplements") may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus as supplemented by the Supplements) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus as supplemented by the Supplements is not addressed. Prior to relying on the information contained in the Prospectus as supplemented by the Supplements you must ascertain from the Prospectus as supplemented by the Supplements whether or not you are part of the intended addressees of the information contained therein.

 

The Notes to be offered under the Programme and the Prospectus as supplemented by the Supplements have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and are subject to US tax law requirements. Subject to certain exceptions, these Notes may not be offered, sold or delivered in the United States or to or for the account of US persons (as defined in Regulation S under the Securities Act).

 

Your right to access the Prospectus as supplemented by the Supplements and this service is conditional upon complying with the above requirements.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PSPPGUCPAUPBGWB